Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization

被引:38
作者
Zucchelli, S
Roccasecca, R
Meola, A
Ercole, BB
Tafi, R
Dubuisson, J
Galfré, G
Cortese, R
Nicosia, A
机构
[1] Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy
[2] Inst Pasteur, IBL, CNRS, UMR8526, F-59019 Lille, France
关键词
D O I
10.1053/jhep.2001.22175
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) contains a principal neutralization epitope, and anti-HVR1 antibodies have been shown to possess protective activity in ex vivo neutralization experiments. However, the high rate of variability of this antigenic fragment may play a major role in the mechanism of escape from host immune response and might represent a major obstacle to developing an HCV vaccine. Thus, even if direct experimental evidence of the neutralizing potential of anti-HVR1 antibodies by active immunization is still missing, the generation of a vaccine candidate with a cross-reactive potential would be highly desirable. To overcome the problem of HVR1 variability, we have engineered cross-reactive HVR1 peptide mimics (mimotopes) at the N terminus of the E2 ectodomain in plasmid vectors suitable for genetic immunization. High levels of secreted and biologically active mimotope/E2 chimeras were obtained by transient transfection of these plasmids in cultured cells. All plasmids elicited anti-HVR1 antibodies in mice and rabbits with some of them leading to a cross-reacting response against many HVR1 variants from natural isolates. Epitope mapping revealed a pattern of reactivity similar to that induced by HCV infection, In contrast, plasmids encoding naturally occurring HVR1 sequences displayed either on full-length E2 in the context of the whole HCV structural region, or on a soluble, secreted E2 ectodomain, did not induce a cross-reacting anti-HVR1 response.
引用
收藏
页码:692 / 703
页数:12
相关论文
共 62 条
[1]   Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view [J].
Abrignani, S .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1997, 19 (01) :47-55
[2]   Perspectives for a hepatitis C virus vaccine [J].
Abrignani, S ;
Rosa, D .
CLINICAL AND DIAGNOSTIC VIROLOGY, 1998, 10 (2-3) :181-185
[3]   TO C OR NOT TO C - THESE ARE THE QUESTIONS [J].
ALTER, HJ .
BLOOD, 1995, 85 (07) :1681-1695
[4]   Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [J].
Boyer, JD ;
Ugen, KE ;
Wang, B ;
Agadjanyan, M ;
Gilbert, L ;
Bagarazzi, ML ;
Chattergoon, M ;
Frost, P ;
Javadian, A ;
Williams, WV ;
Refaeli, Y ;
Ciccarelli, RB ;
McCallus, D ;
Coney, L ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (05) :526-532
[5]   GENETIC-HETEROGENEITY OF HEPATITIS-C VIRUS - QUASI-SPECIES AND GENOTYPES [J].
BUKH, J ;
MILLER, RH ;
PURCELL, RH .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :41-63
[6]   Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].
Calarota, S ;
Bratt, G ;
Nordlund, S ;
Hinkula, J ;
Leandersson, AC ;
Sandström, E ;
Wahren, B .
LANCET, 1998, 351 (9112) :1320-1325
[7]   A METHOD TO PREDICT FUNCTIONAL RESIDUES IN PROTEINS [J].
CASARI, G ;
SANDER, C ;
VALENCIA, A .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (02) :171-178
[8]  
CERINO A, 1993, J IMMUNOL, V151, P7005
[9]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[10]   VACCINATION OF CHIMPANZEES AGAINST INFECTION BY THE HEPATITIS-C VIRUS [J].
CHOO, QL ;
KUO, G ;
RALSTON, R ;
WEINER, A ;
CHIEN, D ;
VANNEST, G ;
HAN, J ;
BERGER, K ;
THUDIUM, K ;
KUO, C ;
KANSOPON, J ;
MCFARLAND, J ;
TABRIZI, A ;
CHING, K ;
MOSS, B ;
CUMMINS, LB ;
HOUGHTON, M ;
MUCHMORE, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1294-1298